<DOC>
	<DOC>NCT02353273</DOC>
	<brief_summary>The objective of this study is to evaluate the systemic exposures of WH-1 ointment which includes Salvigenin and Asiaticoside A in subjects with chronic diabetic foot ulcers following topical application of WH-1.</brief_summary>
	<brief_title>The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers</brief_title>
	<detailed_description>This trial is designed as an open label, non-comparative study to evaluate the pharmacokinetic profiles of salvigenin and asiaticoside A in subjects who received the treatment of WH-1 ointment for diabetic foot ulcers. A total of 12 subjects will be completed in study. Each subject will be applied the one dose of WH-1 ointment on Day 1 following with the blood sampling collection, then twice a day of WH-1 application from Day 2 to Day 13, and another blood sampling collection scheduled on Day 14 after one dose application.</detailed_description>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1. Male or female is at least 20 years of age; 2. Diabetes mellitus (type I or II) was diagnosed with an HbA1c ≤ 12.0% measured during screening or within three months prior to randomization; 3. The target diabetic foot ulcer must have the following characteristics: 1. ≤ Grade 2 per Wagner Ulcer Classification System; 2. Lower limbs; 3. Noinfected; 4. A crosssectional area of between 1 and 25 cm2 postdebridement; 4. If female and of childbearing potential has a negative pregnancy test and is neither breastfeeding or intending to become pregnant during the study; 5. Able and willing to follow with study scheduled visits, comply with study procedures, and sign the informed consent. 1. Acute Charcot' s neuroarthropathy as determined by clinical and/or radiographic examination; 2. Poor nutritional status defined as an albumin &lt; 2.5 g/dL; 3. AST and/or ALT &gt; 3X of the normal upper limit; 4. Clearance of Creatinine (Ccr) &lt; 30 ml/min; 5. Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 4 weeks prior to enroll; 6. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse problem, determined from the subject' s medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance 7. Subjects who have received an experimental agent within 30 days, prior to enroll. 8. Subjects who have received WH1 ointment within 30 days, prior to enroll. 9. Subjects who have history of smoking (define as more than 20 cigarettes per day) within 3 months prior to admission to the Hospital site. 10. Judged by the investigator not to be suitable for the study for any other reason.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>WH-1,Diabetic Foot,Ulcer</keyword>
</DOC>